Skip to content
cccskills
FreePublished on GitHub

es-cushing-screening-tests-for-hypercortisolism-recurrence

This skill recommends using biochemical tests to screen for hypercortisolism to detect recurrence in patients with ACTH-dependent Cushing's syndrome after surgical remission. It is triggered during postoperative follow-up when the HPA axis has recovered, annually, or sooner if clinical signs of hypercortisolism (e.g., weight gain, hypertension, glucose intolerance) or abnormal late-night salivary cortisol/UFC appear.

The English summary is being prepared. Showing the original description.

See how to install

Files included (1)

  • SKILL.md3.1 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Using Tests to Screen for Hypercortisolism to Assess for Recurrence in ACTH-Dependent Cushing's Syndrome

STEP 1 — Gather Information

Collect postoperative timing, HPA axis recovery status, symptoms (weight gain, hypertension, glucose intolerance, fatigue, mood changes), prior biochemical remission values, and imaging if available. Obtain late-night salivary cortisol, urine free cortisol (UFC), or low-dose dexamethasone suppression test per local protocol.

STEP 2 — Rule In / Rule Out

Is there a clinical suspicion of recurrence (new/significant symptoms) OR an abnormal screening test (late-night salivary cortisol > upper limit of normal, UFC > 2× ULN, or failure to suppress cortisol with dexamethasone)?

  • Yes: Proceed to confirmatory testing.
  • No: Continue routine surveillance (clinical assessment annually and biochemical testing every 6–12 months).

STEP 3 — Classify or Stratify

If screening test is abnormal, repeat the same test under standardized conditions (avoid stress, illness, medication interference).

  • Repeat normal: Consider false positive; maintain routine surveillance.
  • Repeat abnormal: Proceed to definitive evaluation (pituitary MRI, petrosal sinus sampling if ACTH-dependent source uncertain, or adrenal imaging if adrenal source suspected).

STEP 4 — Decide

If imaging confirms a lesion suggestive of recurrent ACTH source: discuss repeat transsphenoidal surgery, radiation therapy, medical therapy, or bilateral adrenalectomy based on lesion resectability, patient preference, and comorbidities.
If no lesion identified but biochemical evidence persists: consider empirical medical therapy (steroidogenesis inhibitor) or repeat imaging in 3–6 months.

Clinical Guardrails / Mimics / Pitfalls

Do not diagnose recurrence on a single abnormal test without confirmation due to assay variability, stress, or medication effects. Avoid overtreatment of borderline results; ensure HPA axis has recovered before interpreting cortisol levels. Do not neglect subtle symptoms (e.g., mild weight gain) as they may precede biochemical relapse.

Concrete Clinical Example

A 42‑year‑old woman with ACTH‑dependent Cushing’s disease underwent transsphenoidal surgery; 14 months postoperatively she reported 5 kg weight gain and new‑onset hypertension. Late‑night salivary cortisol was 1.8× ULN; repeat test remained elevated. Pituitary MRI showed a 6 mm enhancing lesion. She opted for repeat transsphenoidal surgery, achieving postoperative UFC < ULN and symptom resolution.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill